Skip to main content

Table 2 Regression models evaluating the effect of statin treatment on men with ED (statin vs placebo groups) for each subscale (1-3) of the MED-QoL-R

From: Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial

 

N

Proportionate difference between study arms and 95% CI (regression model)

 

Mean values at close of trial (unadjusted values)

    

Severe ED

Mild/moderate ED

Total MED-QoL-R

109

0.16 (0.01, 0.30)

Statin

66.1 (58.1, 74.1)

70.7 (62.4, 78.9)

Placebo

58.3 (48.5, 68.2)

68.7 (61.6, 75.9)

Feeling of control (Subscale 1)

61#

0.40 (0.24, 0.53)*

Statin

60.7 (52.3, 69.2)

67.2 (59.6, 74.9)

Placebo

51.6 (41.4, 61.9)

63.8 (56.6, 71.1)

Initiating intimacy (Subscale 2)

107

0.08 (0.12, 0.26)

Statin

67.3 (58.1, 76.6)

72.8 (63.8, 81.8)

Placebo

62.7 (51.4, 74.1)

71.5 (64.0, 79.0)

Emotion response (Subscale 3)

104

0.25 (0.05, 0.41)*

Statin

75.7 (65.8, 85.5)

74.2 (64.2, 84.1)

   

Placebo

64.4 (50.7, 78.0)

74.3 (65.9, 82.6)

  1. MED-QoL-R: Revised male erectile dysfunction-specific quality of life. Column 3 provides the estimated proportionate difference between the study arms (1-exp(model coefficient). Thus 0.4 represents a 40% lower value in the Placebo arm compared to the Statin arm. Regression models (bootstrapped n = 3000) for each subscale were specified with treatment arm, ED severity, arm by severity, and baseline testosterone, cardiovascular risk, and time on treatment as variables. #The number of patients who completed sufficient SEP Diaries (eg encounters) for inclusion in the analysis was lower than for most other outcomes-however for factor 1 (but not the other factors) the number of reported encounters was a very strong predictor of the outcome, and was therefore included in the model. *p < 0.05.